Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)butanoate is a synthetic small molecule belonging to the indenoisoquinoline class of compounds. Indenoisoquinolines are aromatic polycyclic molecules that have been investigated for their potential as topoisomerase I inhibitors and possible antineoplastic (anticancer) agents. This compound is considered experimental and has not been approved for clinical use. Its mechanism of action is presumed to involve inhibition of DNA topoisomerase I by stabilizing the cleavable complex between DNA and the enzyme during replication or transcription processes. The compound has primarily been studied in preclinical settings as a chemical probe or lead structure for further drug development within oncology research.[1][2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(5,11-dioxo-5H-indeno[1,2-c]isoquinolin-6(11H)-yl)butanoate.